DC therapy for prostate cancer

References

• Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. 7 Urol 1994;151:1283–90.
   PubMed Web of Science ®Google Scholar
• Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. Cancer 7 Clin 2002;52: 23–47.
   Google Scholar
• Moul JW. Rising PSA after local therapy failure: immediate vsdeferred treatment. Oncology (Huntington) 1999;13:985-90, 93 [Discussion 93–5, 99].
   Google Scholar
• Greenlee RT, Murray T, Bolden S et al. Cancer statistics, 2000.Cancer y Clin 2000;50:7–33.
   PubMed Web of Science ®Google Scholar
• Moul JW. Prostate specific antigen only progression of prostatecancer. 7 Urol 2000;163:1632–42.
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA et al. Natural history ofprogression after PSA elevation following radical prostatectomy. Am Med Assoc 1999;281:1591–7.
   PubMed Web of Science ®Google Scholar
• Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999;26:162— 73.
   PubMed Web of Science ®Google Scholar
• Smaletz 0, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. 7 Clin Oncol 2002;20: 3972— 82.
   Google Scholar
• Martel CL, Gumerlock PH, Meyers FJ et al. Current strategiesin the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171–87.
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271 —96.
   PubMed Web of Science ®Google Scholar
• Slovin SE Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Hematol Oncol Clin N Am 2001;15:477–96.
   PubMed Web of Science ®Google Scholar
• Grabbe S, Beissert S, Schwarz T et al. Dendritic cells as initiatorsof tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16:117— 21.
   PubMedGoogle Scholar
• Zinkernagel PC, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701.
   PubMed Web of Science ®Google Scholar
• Mitropoulos D, Kooi S, Rodriguez-Villanueva J et al. Character-ization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin Exp Immunol 1994;97:321— 7.
   PubMed Web of Science ®Google Scholar
• Ivshina AV, Zhumagazin Zh D, Zabotina TN, et al. [Effect of thespread of the process and treatment on the phenotype of peripheral blood lymphocytes in patients with prostatic cancer]. Urol Nefrol (Mosk) 1995:36–8.
   PubMedGoogle Scholar
• Healy CG, Simons JW, Carducci MA et al. Impaired expressionand function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998;32:109— 19.
   PubMedGoogle Scholar
• Salgaller ML, Lodge PA, McLean JG et al. Report of immunemonitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with H1A-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998;35:144 — 51.
   PubMed Web of Science ®Google Scholar
• Troy A, Davidson P, Atkinson C et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. 7 Urol 1998;160: 214–9.
   Google Scholar
• Troy AJ, Summers KL, Davidson PJ et al. Minimal recruitmentand activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585–93.
   PubMed Web of Science ®Google Scholar
• Troy AJ, Davidson P, Atkinson C et al. The contribution of dendritic cells to immune responses against urological cancers. Urol Oncol 1998;4:17–23.
   PubMedGoogle Scholar
• Coventry BJ, Lee PL, Gibbs D et al. Dendritic cell density andactivation status in human breast cancer - CD1a, CMRF -44, CMRF-56 and CD-83 expression. Br7 Cancer 2002;86:546–51.
   PubMed Web of Science ®Google Scholar
• Sallusto E Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony- stimulating factor plus inter-leukin 4 and downregulated by tumour necrosis factor-a. 7 Exp Med 1994;179: 1109–18.
   Google Scholar
• Gabrilovich DI, Corak J, Ciernik IF et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483–90.
   PubMed Web of Science ®Google Scholar
• Havranek EG, Whelan MA, Greenhalgh R et al. Advances in prostate cancer immunotherapy. Surgical Oncol 2002;11:35–45.
   PubMed Web of Science ®Google Scholar
• Dummer W, Becker JC, Schwaaf A et al. Elevated serum levels ofinterleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5:67–8.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–103.
   PubMed Web of Science ®Google Scholar
• Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompat-ibility complex class I products and peripheral CD8+ T cell tolerance. 7 Exp Med 2002;196:1627–38.
   PubMed Web of Science ®Google Scholar
• Shurin GV, Aalamian M, Pirtskhalaishvili G et al. Human prostate cancer blocks the generation of dendritic cells from CD34 hematopoietic progenitors. Eur Urol 2001;39:37–40.
   PubMed Web of Science ®Google Scholar
• Burch PA, Breen JK, Buckner JC et al. Priming tissue-specificcellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175–82.
   PubMed Web of Science ®Google Scholar
• Valone FH, Small E, MacKenzie M et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer 2001;7(Suppl 2):S53–61.
   Google Scholar
• Kennedy-Smith AG, McKenzie JL, Owen MC et al. Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. 7 Urol 2002;168:741–7.
   PubMed Web of Science ®Google Scholar
• Elsasser-Beile U, von Kleist S, Sauther W et al. Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. Br Cancer 1993;68:32–6.
   Google Scholar
• Blades RA, Keating PJ, McWilliam LJ et al. Loss of HLA class Iexpression in prostate cancer: implications for immunotherapy. Urology 1995;46:681–7.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Restifo NP, Walsh JC et al. Molecular characteriza- tion of defective antigen processing in human prostate cancer. Natl Cancer Inst 1995;87:280–5.
   Google Scholar
• Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol 1992;10:617–44.
   PubMed Web of Science ®Google Scholar
• Tjoa BA, Murphy GP. Progress in active specific immunother-apy of prostate cancer. Sem Surg Oncol 2000;18:80–7.
   PubMedGoogle Scholar
• Chen ME, Lin SH, Chung LW et al. Isolation and characteriza-tion of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. 7 Biol Chem 1998;273:17618–25.
   Google Scholar
• Brenner PC, Rettig WJ, Sanz-Moncasi MP et al. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. Urol 1995;153:1575–9.
   Web of Science ®Google Scholar
• Wright GL, Jr, Beckett ML, Lipford GB et al. A novel prostatecarcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27. Int 7 Cancer 1991;47:717–25.
   PubMed Web of Science ®Google Scholar
• Slovin SF', Livingston PO, Rosen N et al. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin Oncol 1997;23:41–8.
   Google Scholar
• Heiser A, Coleman D, Dannull J et al. Autologous dendritic cellstransfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate rumors. 7 Clin Invest 2002;109:409–17.
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded den-dritic cells. 7 Clin Oncol 2000;18:3894–903.
   PubMed Web of Science ®Google Scholar
• Murphy G, Tjoa B, Ragde H et al. Phase I clinical trial: T-celltherapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371–80.
   PubMed Web of Science ®Google Scholar
• Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001;2:789–92.
   PubMed Web of Science ®Google Scholar
• Cavacini LA, Duval M, Eder JP et al. Evidence of determinantspreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin Cancer Res 2002;8:368–73.
   PubMed Web of Science ®Google Scholar
• Gulley J, Chen AP, Dahut W et al. Phase I study of a vaccineusing recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53:109–17.
   PubMed Web of Science ®Google Scholar
• Aalamian M, Tourkova IL, Chatta GS et al. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. 7 Urol 2003;170:2026–30.
   PubMed Web of Science ®Google Scholar
• Harada M, Kobayashi K, Matsueda S et al. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24 ± prostate cancer patients. Prostate 2003;57:i52–9.
   Web of Science ®Google Scholar
• Perambakam S, Xue BH, Sosman JA et al. Induction of Tc2 cellswith specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2002;51:263–70.
   PubMed Web of Science ®Google Scholar
• Terasawa H, Tsang KY, Gulley J et al. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 2002;8:41–53.
   PubMed Web of Science ®Google Scholar
• Heiser A, Dahm P, Yancey D et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimu-late prostate-specific CTL responses in vitro. y Immunol 2000;164:5508–14.
   Google Scholar
• Harvey TJ, Hooper JD, Myers SA et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. y Biol Chem 2000;275: 37397–406.
   Google Scholar
• Clements J, Hooper J, Dong Y et al. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001;382:5–14.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Chang A, Scorilas A et al. Genomic organization ofthe human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000;276:125–33.
   PubMed Web of Science ®Google Scholar
• Nelson PS, Gan L, Ferguson C et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999;96:3114–9.
   PubMed Web of Science ®Google Scholar
• Stephenson SA, Verity K, Ashworth LK et al. Localization of anew prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. 7 Biol Chem 1999;274:23210–4.
   PubMed Web of Science ®Google Scholar
• Hooper JD, Bui LT, Rae FK et al. Identification and character-ization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 2001;73:117–22.
   Google Scholar
• Diamandis EP, Okui A, Mitsui S et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295–300.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Scorilas A, Jung K et al. Molecular cloning of thehuman kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. y Biol Chem 2001;276:53–61.
   Google Scholar
• Yousef GM, Obiezu CV, Luo LY et al. Prostase/KLK-L1 is a newmember of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999;59:4252–6.
   PubMed Web of Science ®Google Scholar
• Hural JA, Friedman RS, McNabb A et al. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. y Immunol 2002;169:557–65.
   Google Scholar
• Murphy GP, Greene TG, Tino WT et al. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. y Urol 1998;160:2396–401.
   PubMed Web of Science ®Google Scholar
• Lange PH. PROSTASCINT scan for staging prostate cancer. Urology 2001;57:402–6.
   PubMed Web of Science ®Google Scholar
• Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nuclear Med 1998;23: 672–7.
   Google Scholar
• Troyer JK, Beckett ML, Wright GL, Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232–42.
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al. In vitrocharacterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237–43.
   PubMed Web of Science ®Google Scholar
• Horiguchi Y, Nukaya I, Okazawa K et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific mem-brane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002;8:3885–92.
   PubMed Web of Science ®Google Scholar
• Lu J, Celis E. Recognition of prostate rumor cells by cytotoxic Tlymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62:5807–12.
   PubMed Web of Science ®Google Scholar
• Schroers R, Shen L, Rollins L et al. Identification of MHC classThrestricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 2003;9:3260–71.
   PubMed Web of Science ®Google Scholar
• Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin N Am 1993;20:589–95.
   PubMed Web of Science ®Google Scholar
• Heller JE. Prostatic acid phosphatase: its current clinical status. yUrol 1987;137:1091–103.
   Google Scholar
• Valone FH, Yang DM, Ruegg CL. Dendritic cell immunother-apy of prostate cancer: Preclinical models of autoimmune prostatitis and early clinical experience. Cancer Res Therapy Control In press.
   Google Scholar
• Morris MJ, Scher HI. Optimizing targeted therapy and devel-oping novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. Crit Rev Oncol Hematol 2003;46 Supp1:21–31.
   Google Scholar
• Bubley GJ, Carducci M, Dahut W et al. Eligibility and responseguidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. y Clin Oncol 1999;17:3461–7.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321–4.
   PubMed Web of Science ®Google Scholar
• Tjoa BA, Simmons SJ, Elgamal A et al. Follow-up evaluation of aphase II prostate cancer vaccine trial. Prostate 1999;40:125–9.
   PubMed Web of Science ®Google Scholar
• Simmons SJ, Tjoa BA, Rogers M et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999;39:291–7.
   PubMedGoogle Scholar
• Kundu SK, Engleman E, Benike C et al. A pilot clinical trial ofHIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998;14:551–60.
   PubMed Web of Science ®Google Scholar